Fintel studies that on May 23, 2023, HC Wainwright & Co. reiterated protection of Anixa Biosciences (NASDAQ:ANIX) with a Buy suggestion.
Analyst Price Forecast Suggests 210.43% Upside
As of May 11, 2023, the typical one-year worth goal for Anixa Biosciences is 10.71. The forecasts vary from a low of 9.09 to a excessive of $12.60. The common worth goal represents a rise of 210.43% from its newest reported closing worth of three.45.
See our leaderboard of corporations with the biggest worth goal upside.
The projected annual income for Anixa Biosciences is 0MM. The projected annual non-GAAP EPS is -0.63.
What is the Fund Sentiment?
There are 68 funds or establishments reporting positions in Anixa Biosciences. This is unchanged during the last quarter. Average portfolio weight of all funds devoted to ANIX is 0.01%, a rise of 53.92%. Total shares owned by establishments elevated within the final three months by 2.57% to 4,020K shares. The put/name ratio of ANIX is 0.07, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 928K shares representing 3.00% possession of the corporate. No change within the final quarter.
UBS Group holds 639K shares representing 2.07% possession of the corporate. In it is prior submitting, the agency reported proudly owning 623K shares, representing a rise of two.57%. The agency decreased its portfolio allocation in ANIX by 19.30% during the last quarter.
VEXMX – Vanguard Extended Market Index Fund Investor Shares holds 335K shares representing 1.08% possession of the corporate. In it is prior submitting, the agency reported proudly owning 328K shares, representing a rise of two.13%. The agency decreased its portfolio allocation in ANIX by 14.94% during the last quarter.
Geode Capital Management holds 274K shares representing 0.89% possession of the corporate. No change within the final quarter.
ITOT – iShares Core S&P Total U.S. Stock Market ETF holds 202K shares representing 0.65% possession of the corporate. In it is prior submitting, the agency reported proudly owning 214K shares, representing a lower of 5.69%. The agency decreased its portfolio allocation in ANIX by 19.06% during the last quarter.
Anixa Biosciences Background Information
(This description is supplied by the corporate.)
Anixa Biosciences Inc. is a biotechnology firm growing quite a few applications addressing most cancers and infectious illness. Anixa’s therapeutics portfolio features a most cancers immunotherapy program which makes use of a novel sort of CAR-T, often known as chimeric endocrine receptor T-cell (CER-T) know-how, and a Covid-19 therapeutics program targeted on inhibiting sure viral protein perform. The firm’s vaccine portfolio features a vaccine to forestall breast most cancers, and particularly triple unfavorable breast most cancers (TNBC), probably the most lethal type of the illness, and a vaccine to forestall ovarian most cancers. These vaccine applied sciences deal with immunizing towards particular proteins which were discovered to be expressed in sure types of most cancers. Anixa regularly examines rising applied sciences in complementary fields for additional improvement and commercialization.
Key filings for this firm:
This story initially appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.